Latest Conference Articles

Novartis highlighted key findings at AAD and AAAAI, showcasing Cosentyx's flexible dosing for hidradenitis suppurativa and remibrutinib’s efficacy for chronic spontaneous urticaria.

Elizabeth Berry, MD, FAAD, reviewed dysplastic nevi as risk markers and highlighted the need for more data on severe cases at AAD 2025.

Li discusses microneedling innovations, global techniques, safety, and future trends in dermatology, including integration with RF and PRP.

Christopher Bunick, MD, PhD, reviewed the evolving role of antibiotics, emphasizing antibiotic stewardship, the gut-skin connection, and the importance of narrow-spectrum antibiotics at AAD 2025.

Compared to placebo, there was a 70% reduction in IgE levels in children ages 0.5 to 6 after 16 weeks of therapy.

Catch up on coverage from the final day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

Christopher Bunick, MD, PhD, discussed how to interpret recent benzene research as clinicians await regulatory guidance for benzoyl peroxide.

New results from Alumis show a positive clinical response and safety profile after 52 weeks of treatment for patients with plaque psoriasis.

Gold highlighted the growing role of energy-based devices in acne treatment during his AAD session.

Anabela Cardoso, MD, discussed lebrikizumab’s efficacy in improving itch, skin pain, sleep disturbance, and long-term management in atopic dermatitis.

Efficacy, safety, and pharmacokinetic data support the use of vilobelimab in treating pyoderma gangrenosum and hidradenitis suppurativa.

Johnson & Johnson’s JNJ-2113 showed promise for PsO, achieving high skin clearance with a strong safety profile.

Catch up on coverage from the fourth day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

At AAD 2025, Karan Lal, DO, MS, FAAD, presented clinical insights on insulated microneedling tips, grounding pad issues in monopolar radiofrequency, and more.

Gold discussed breakthrough treatments for scars, including silicone, energy-based devices, and radiation therapy.

Christopher Bunick, MD, PhD, explains what comes next for clinicians and patients live at AAD 2025.

Stark highlighted Bimzelx’s role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.

Lio shared insights on minimizing pain in dermatologic procedures, highlighting practical techniques from his AAD 2025 presentations.

According to a poster from AAD, the National Psoriasis Foundation’s treatment goals were used as a benchmark to determine the risk of developing psoriatic arthritis after initiating biologics.

Catch up on coverage from the third day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

Gold emphasized the necessity of recognizing and managing complications in aesthetic dermatology to ensure patient safety and optimal outcomes.

AbbVie’s phase 2 study demonstrates how upadacitinib reduces type 1 inflammation and boosts melanocyte biomarkers to drive vitiligo response.

Findings suggest that most patients on risankizumab met or exceeded the National Psoriasis Foundation’s treatment goals.

Adamson dives deep into artificial intelligence, molecular testing, and melanoma overdiagnosis.

At AAD 2025, Raj Chovatiya, MD, PhD, MSCI, explored the role of social determinants in AD, HS, and PsO, emphasizing the need for improved clinical recognition and inclusive research.

Anabela Cardoso, MD, provides data on the phase 3 BRAVE-AA-PEDS trial, the largest JAK inhibitor study dedicated to adolescents with severe alopecia areata, at AAD.

Catch up on coverage from the second day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

April Armstrong, MD, MPH, FAAD, discusses her late-breaking presentation at AAD on the treatment response in patients with moderate to severe chronic CHE treated with delgocitinib.